You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

programmed cell death receptor 1 (PD-1)

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer, Solid Tumor Trial in Fairfax (BBP-398 with nivolumab)

Recruiting
  • Non Small Cell Lung Cancer
  • Solid Tumor
  • BBP-398 with nivolumab
  • Springdale, Arkansas
  • +6 more
Jan 27, 2023

Lung Cancer Trial in Assiut (Observational Study ( Tissue Biopsy ))

Completed
  • Lung Cancer
  • Observational Study ( Tissue Biopsy )
  • Assiut, Egypt
    Assiut University
Oct 18, 2021

Peripheral T-cell Lymphoma Trial in Shanghai (PD-1 antibody+ HDAC inhibitor)

Recruiting
  • Peripheral T-cell Lymphoma
  • PD-1 antibody+ HDAC inhibitor
  • Shanghai, Shanghai, China
    Dongmei Ji
Dec 3, 2021

NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Capsulized Fecal Microbiota Transplant
  • +2 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Aug 12, 2021

NSCLC, Low Dose Radiotherapy, Stereotactic Body Radiotherapy Trial in Chengdu (Low Dose Radiotherapy, stereotactic body

Not yet recruiting
  • NSCLC
  • +3 more
  • Low Dose Radiotherapy
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Nov 11, 2022

EBV Infection Trial in Beijing (PD1 antibody, lenalidomide)

Recruiting
  • EBV Infection
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Jan 4, 2022

NSCLC Trial (Drug-eluting beads bronchial arterial chemoembolization, Programmed Cell Death Protein 1 Inhibitor)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Drug-eluting beads bronchial arterial chemoembolization
  • Programmed Cell Death Protein 1 Inhibitor
  • (no location specified)
Feb 17, 2022

Soluble Programmed Death 1 isDiagnostic Biomarker of ILD in

Not yet recruiting
  • Rheumatoid Arthritis
  • soluble programmed death 1biomarker
  • (no location specified)
Jan 11, 2022

NSCLC Trial in Guangzhou (PEF, Anti-PD-1 mAb)

Recruiting
  • NSCLC
  • PEF
  • Anti-PD-1 monoclonal antibody
  • Guangzhou, Guangdong, China
    The first Affiliated Hospital of Guangzhou Medical University
Aug 3, 2023

Advanced NSCLC Trial (BNT116, Cemiplimab)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jan 3, 2023

Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +4 more
  • KRAS-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

EBV Infection Trial in Suzhou (PD-1 mAb)

Recruiting
  • EBV Infection
  • PD-1 monoclonal antibody
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Sep 1, 2021

Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Refractory Non-Small Cell Lung Cancer
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023

Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

Not yet recruiting
  • Advanced Non Small Cell Lung Cancer
  • (no location specified)
Oct 24, 2023

Head and Neck Squamous Cell Carcinoma Trial (Pembrolizumab, Cisplatin, Paclitaxel-albumin)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Oct 25, 2023

Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +6 more
  • TP53-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Alirocumab and Cemiplimab
  • (no location specified)
Jan 31, 2023

NSCLC Trial in China (Pembrolizumab, Lenvatinib, Placebo for lenvatinib)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +2 more
  • Hefei, Anhui, China
  • +16 more
Oct 14, 2022

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

Esophageal Squamous Cell Carcinoma (ESCC), PD-1 Inhibitors Trial in Zhengzhou (IBI110+Sintilimab)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • PD-1 Inhibitors
  • Zhengzhou, Henan, China
    Feng Wang
Oct 9, 2023

Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Cadonilimab combined Anlotinib)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Cadonilimab combined Anlotinib
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 6, 2023

Hepatocellular Carcinoma Trial in Yichang (Sintilimab)

Recruiting
  • Hepatocellular Carcinoma
  • Yichang, Hubei, China
    Department of Medical Oncology, Central Hospital of Yichang City
Sep 1, 2023

Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma Trial in New York (Nivolumab, Atezolizumab, Radiation &

Terminated
Has Results
  • Metastatic Renal Cell Carcinoma
  • Metastatic Urothelial Carcinoma
  • New York, New York
    Weill Cornell Medicine - New York Presbyterian Hospital
Aug 26, 2021

Non Small Cell Lung Cancer Recurrent Trial (Toripalimab, Anlotinib and Chemotherapy)

Not yet recruiting
  • Non Small Cell Lung Cancer Recurrent
  • Toripalimab, Anlotinib and Chemotherapy
  • (no location specified)
Apr 24, 2023

Lung Cancer, Non-Small Cell Trial in Worldwide (Pembrolizumab, Dostarlimab, GSK4428859A)

Recruiting
  • Lung Cancer, Non-Small Cell
  • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
  • +14 more
Dec 26, 2022